arrow
M

Marco Krengli

University of Padua
H指数:46
被引数:6,752

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Radiomic approach to support multidisciplinary tumor board decision-making in locally advanced non-small cell lung cancer

基于放射组学方法支持局部晚期非小细胞肺癌的多学科肿瘤委员会决策制定

2025-12-190
OAAI
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting

AIMN、AIOM、AIRO、SIU、SIUrO 和 Meet-URO 关于意大利前列腺癌中PSMA PET成像使用的联合调查:技术方面和初始分期设置

2025-12-010
OAAI
A PHASE 1, FIRST-IN-HUMAN STUDY OF REGORAFENIB PLUS TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED, IDH WILDTYPE GLIOBLASTOMA: THE REGOMA-2 TRIAL

一项关于瑞戈非尼联合替莫唑胺,在有或无放疗情况下,用于新诊断的MGMT甲基化、IDH野生型胶质母细胞瘤患者的I期首个人类研究:REGOMA-2试验

2025-11-010
OAAI
Beyond Molecular Characterization: The Impact of Age-Adjusted Charlson Comorbidity Index in Glioblastoma Patients Treated with Radio or Radio-Chemotherapy

超越分子表征:年龄调整的Charlson合并症指数在经放疗或放化疗治疗的胶质母细胞瘤患者中的影响

2025-10-230
OAAI
Solitary fibrous tumour: histological discoveries, behavioural aspects, risk assessment and therapeutical approaches

孤立性纤维瘤:组织学发现、行为特征、风险评估和治疗方法

2025-10-220
OA
A PHASE 1, FIRST-IN-HUMAN STUDY OF REGORAFENIB PLUS TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED, IDH WILDTYPE GLIOBLASTOMA: REGOMA-2 TRIAL

一项关于瑞戈非尼联合替莫唑胺,无论是否联用放疗,在 newly diagnosed MGMT methylated, IDH wildtype glioblastoma 患者中的首次人体研究的第1阶段:REGOMA-2试验

2025-10-010
OAAI
Oligometastatic Mesothelioma Treated with Ablative Radiotherapy (OMAR): A Multicenter Study

寡转移性间皮瘤经消融放疗治疗(OMAR):一项多中心研究

2025-08-270
OA
Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery
2024-10-012
OAAI
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group
2024-05-012
OAAI
Primary vascular tumors of bone: A comprehensive literature review on classification, diagnosis and treatment
2024-03-012
OAAI